Hem D. Shukla, PhD

Hem D. Shukla received his PhD in Biochemistry at R. D. University Jabalpur in India and completed his post-doctoral training from University of Massachusetts. Later, he finished his training in cancer biology from National Institutes of Health and Institute of Cell Engineering at Johns Hopkins University School of Medicine.

Dr. Shukla is currently working as an active team member in the Division of Translational Radiation Sciences (DTRS, UMB) under the leadership of Dr. William Regine MD. The main focus of his research is radiation induced modulation of immuno-suppressive tumor microenvironment in pancreatic and non-small cell lung cancers. His lab is also interested in cancer immunotherapy, and using targeted therapeutics to inhibit specific pathways that are altered in cancers. 

Dr. Shukla`s lab is located at the Bressler research building (BRB) of the school of Medicine and is highly focused on translational research employing Photon and Proton-beam radiation (Maryland Proton Treatment Center) using different tumor xenografts and patient derived tumor organoid models.

Pancreatic cancer, tumor microenvironment, chemo and radiation resistance.

1. Roy S, Dukic T, Keepers Z, Shukla HD et al. 2024. SOX2 and OCT4 mediate radiation and drug resistance in pancreatic tumor organoids. Cell Death Discovery. 10, 106, https://doi.org/10.1038/s41420-024-01871-1.

2. Roy S, Dukic T, Bhandary B, Tu KJ, Molitoris J, Ko YH, Shukla HD. 2022. 3-Bromopyruvate inhibits pancreatic tumor growth by stalling glycolysis, and dismantling mitochondria in a syngeneic mouse model. Am J Cancer Res. Nov 15;12(11):4977-4987.

3. Leiser D, Samanta S, Eley J, Strauss J, Creed M, Kingsbury T, Staats P N, Bhandary B, Chen M, Dukic T, Roy S, Mahmood J, Vujaskovic Z, Shukla H. D. 2021.  Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer. PLOS ONE, 16, e0258951.

4. Mahmood J, Alexander AA, Samanta S, Kamlapurkar S, Singh P, Saeed A, Carrier F, Cao X,  Shukla HD., Vujaskovic Z. 2020. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers, 12, 1015; doi:10.3390/cancers12041015.

5. Mahmood J, Shukla HD, Soman S, Samanta S, Singh P, Kamlapurkar S, Saeed A, Amin NP and Vujaskovic Z. 2018. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers, 10, 469.
6. Shukla H.D. (2016). Novel Genomics and Proteomics Based Biomarkers to Predict Radiation Response and Normal Radiotoxicity in Cancer Patients for Personalized Medicine. J Cancer Clin. Trials, 1: 3.
7. Mahmood J., Aksinija S., Creed T. M., Pavlovic R., Matsui H., Kimura M., J Molitoris, Shukla H.D., Jackson I. And Z. Vujaskovic (2016). Radiation-induced ED in prostate cancer patients: Recent advances and future directions. Advances in Radiation Oncology, 1: 161-169.
8. Mahmood J., Zaveri, S. R., Murti S., Shukla H. D. and Vujaskovic Z. (2016). Caveolin-1: A novel prognostic biomarker of radio-resistance in lung cancer. International Journal of Radiation Biology, 10.1080/09553002.2016.1222096.
9. Shukla H. D., Mahmood J. and Vujaskovic Z. (2015) Proteo-genomic approach to early diagnosis                      and  prognosis of cancer. Cancer Letters, 369: 28–36.